Make VABYSMO your first choice for rapid* vision gains^1,2

*Nominal P-value <0.05 vs. baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline VA and ≥6 months of follow-up. Assessments were captured around the -6 to +7-day window around each injection visit.

VABYSMO delivers fast* drying after 1 injection in the real world^1,2

*FARETINA-DME: Nominal P-value <0.05 vs baseline and FARETINA-AMD: Nominal P-value <0.01 vs baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline CST measurement (0–30 days before index) between 7 February 2022 and 30 June 2023, and 2+ CST measures in ≤180 days before index and 2+ CST in 180 days post index, excluding CST measurements ≤14 days after an injection. Statistical test for change in CST from baseline.

Most patients achieve early fluid resolution with VABYSMO³

Increase clinical capacity with VABYSMO’s extended durability^1,2,4